Despite premarket gains, shares of AnaptysBio (NASDAQ:ANAB) turned lower on Wednesday following disappointing mid-stage trial data for Johnson & Johnson’s (NYSE:JNJ) anti-inflammatory agent JNJ-67484703, designed similar to ANAB’s lead asset rosnilimab.
An abstract released ahead of a European medical event